Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACH-0143102 · 1 trial · 1 indication
To determine the incidence of the SVR12 after the completion of dosing with ACH-0143102 plus ribavirin, reported as hepatitis C virus ribonucleic acid less than the limit of quantification at that time point.
| Arm | Type | Description |
|---|---|---|
| ACH-0143102 plus ribavirin daily | EXPERIMENTAL | ACH-0143102 loading dose (225 milligrams \[mg\]) on Day 1, followed by maintenance doses (75 mg) on Days 2-84, plus weight-based ribavirin as per label on Days 1-84. |
| Name | Type | Description |
|---|---|---|
| ACH-0143102 | DRUG | - |
| Ribavirin | DRUG | - |
Inclusion Criteria: * Males and females aged 18 years and older. * Clinical diagnosis of hepatitis C with GT1b. * Chronic hepatitis C treatment-naive participants. * Interleukin 28B genotype CC. * HCV ribonucleic acid \> 10,000 international units/milliliter at screening. * Female participants must...
ACH-0143102 is an investigational small molecule being developed for the treatment of chronic hepatitis C infection. It was studied in a Phase 1 clinical trial in combination with ribavirin in treatment-naive patients with hepatitis C virus genotype 1b infection.
ACH-0143102 is a small molecule antiviral agent. Its specific molecular target has not been disclosed in the available information. The drug was evaluated for its safety, tolerability, and antiviral activity in patients with chronic hepatitis C infection.
ACH-0143102 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is currently in early-stage clinical development for chronic hepatitis C infection.
ACH-0143102 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of chronic hepatitis C infection, and its safety and efficacy have not yet been established.
ACH-0143102 has been studied in one clinical trial, identified as NCT01700179. This Phase 1 trial evaluated the safety, tolerability, and antiviral activity of ACH-0143102 plus ribavirin in treatment-naive participants with hepatitis C virus genotype 1b infection. The trial has been completed.
ACH-0143102 is not known to have any alternative names. It is a distinct investigational compound being developed by AstraZeneca for chronic hepatitis C infection. No other names for this drug have been reported in the available information.